These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 19127212

  • 1. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX, Kong L, Weisman LE.
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [Abstract] [Full Text] [Related]

  • 2. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 3. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
    [Abstract] [Full Text] [Related]

  • 4. Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
    Oluola O, Kong L, Fein M, Weisman LE.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2198-200. PubMed ID: 17420212
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA, Gil-Navarro MV, Santos-Rubio MD, Bautista J, Aznar J.
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [Abstract] [Full Text] [Related]

  • 6. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Clemens EC, Chan JD, Lynch JB, Dellit TH.
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM, Kokai-Kun JF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model.
    Sande L, Sanchez M, Montes J, Wolf AJ, Morgan MA, Omri A, Liu GY.
    J Antimicrob Chemother; 2012 Sep; 67(9):2191-4. PubMed ID: 22661572
    [Abstract] [Full Text] [Related]

  • 12. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J.
    Clin Infect Dis; 2008 Jan 15; 46(2):193-200. PubMed ID: 18171250
    [Abstract] [Full Text] [Related]

  • 13. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY, Hsueh PR, Chiang WC, Huang EP, Lin CF, Chang CH, Chen SC, Chen WJ, Chang SC, Lai MS, Chie WC.
    J Infect; 2014 Sep 15; 69(3):259-65. PubMed ID: 24797078
    [Abstract] [Full Text] [Related]

  • 14. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul 15; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

  • 15. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ.
    Clin Infect Dis; 2012 Jan 01; 54(1):51-8. PubMed ID: 22109947
    [Abstract] [Full Text] [Related]

  • 16. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC.
    J Antimicrob Chemother; 2011 Oct 01; 66(10):2386-92. PubMed ID: 21775337
    [Abstract] [Full Text] [Related]

  • 17. [The change and significance of vancomycin minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus isolates from inpatients with lower respiratory tract infection].
    Yang W, He B, Ning YZ, Li Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Apr 01; 36(4):288-92. PubMed ID: 23945344
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM, Rojtman AD.
    Ann Pharmacother; 2010 May 01; 44(5):918-21. PubMed ID: 20354160
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL.
    Diagn Microbiol Infect Dis; 2007 Apr 01; 57(4):413-8. PubMed ID: 17141452
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
    Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS.
    J Antimicrob Chemother; 2006 Aug 01; 58(2):462-5. PubMed ID: 16735425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.